You have selected Encore.
Encore is InterCall's recording replay service and provides the opportunity to listen to the Event for those who were unable to attend it live or who would like to listen again. The Recording will be available four hours after the Event concludes. The date range that the recording will be accessible is listed below. To access the recording, guests will use the Dial-In Number listed below and the Conference ID 2837070.
Encore Dial In Numbers:
UK National Call: 08717000145
UK LocalCall: 08443386600
UK FreeCall: 08009531533
Std International: +44 (0)1452550000
Canada: 1(866) 878-9237
USA: 1 (866) 247-4222
Encore Dates: 13/03/2015 12:00 GMT - 09/04/2015 13:00 GMT
Notes to editors
About Oxford BioMedica®
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex-vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.
For further information please contact
Oxford BioMedica plc
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Tel: +44 (0)1865 783 000
Consilium Strategic Communications – Media Enquiries
Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton/Rosie Phillips
Tel: +44 (0)20 3709 5700